Gastric Motility Disorder Drug Market, By Disorder Type (Upper Digestive Tract and Lower Digestive Tract), By Drug Class (Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors, and Others), By Distribution Channel (Hospit

Gastric Motility Disorder Drug Market, By Disorder Type (Upper Digestive Tract and Lower Digestive Tract), By Drug Class (Antacids, Antidiarrheals, Calcium-channel Blockers, H2 Blockers, Proton Pump Inhibitors, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Gastric motility disorder refers to conditions wherein the stomach takes more or less time than usual to empty its contents. Some common gastric motility disorders include gastroparesis and functional dyspepsia. Gastroparesis occurs when the muscle movements in the stomach are either sluggish or disordered, causing food to get stuck in the stomach for a longer duration than normal. It affects the normal digestive process and often causes nausea, bloating, and vomiting. Similarly, functional dyspepsia involves impaired gastric emptying processes leading to discomfort in the upper abdomen. The exact causes of gastric motility disorders are unknown in many cases; however, they may arise due to damage to the vagus nerve, diabetes, certain medications, surgery, or other underlying health conditions. Currently available drug therapies for gastric motility disorders include prokinetics that aim to stimulate gastric motility and hasten gastric emptying. Given the chronic nature and lack of complete cure for such disorders, the global gastric motility drug market is poised to grow steadily in the coming years.

Market Dynamics:

The global gastric motility drug market is driven by the increasing prevalence of diabetes as it is a high-risk factor for gastroparesis. Extended hospital stays and loss of work productivity associated with gastric motility disorders also contribute to their growing economic burden. This is anticipated to fuel the demand for more effective drug therapies. However, the market potential is restricted by the lack of approved drugs for some types of gastric motility disorders. Moreover, side effects associated with existing drug options pose a major challenge. Development of novel drug formulations with better safety profiles can present lucrative opportunities in this market. Adoption of combination therapies and development of region-specific formulations tailored to address the unmet needs are some key opportunities.

Key Features of the Study:

• This report provides an in-depth analysis of the global gastric motility disorder drug market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global gastric motility disorder drug market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global gastric motility disorder drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastric motility disorder drug market.

Detailed Segmentation-

• Disorder Type:
• Upper Digestive Tract
• Achalasia
• Gastroesophageal Reflux Disease (GERD)
• Gastroparesis
• Dumping Syndrome
• Lower Digestive Tract
• Intestinal Pseudo-obstruction
• Small Intestinal Bacterial Overgrowth (SIBO)
• Pelvic Dyssynergia
• Hirschsprung’s Disease
• Drug Class:
• Antacids
• Antidiarrheals
• Calcium-channel Blockers
• H2 Blockers
• Proton Pump Inhibitors
• Others
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Janssen Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Boehringer Ingelheim
• Eli Lilly and Company
• Bristol Myers Squibb
• Daiichi Sankyo Company, Limited
• Bausch Health Companies
• Mallinckrodt Pharmaceuticals
• Endo Pharmaceuticals
• Eisai Co., Ltd.
• Ferring Pharmaceuticals
• UCB
• Evoke Pharma
• Cadila Pharmaceuticals